QST for Corneal Nerve Function

Status Enrolling by invitation

Clinical Trial Summary

This study is designed to learn more about the impact different types of stimuli, such as heat, cold and vibration, can have on ocular pain response. This is called quantitative sensory testing (QST). Most procedures being performed in this study, except the QST, are standard of care which means they are performed during the participant's routine eye examination.

Clinical Trial Description

Quantitative Sensory Test (QST) is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli for the purpose of characterizing somatosensory function or dysfunction. In this study, we propose to evaluate corneal nerve functions in patients with corneal nerve abnormalities by QST and correlate the nerve functions with symptoms, clinical signs and nerve morphology detected by In-Vivo Confocal Microscopy (IVCM). Identification of corneal nerve functions and correlations with other findings may help us to understand underlying pathological mechanisms of the disease and may guide us toward new treatment targets. We hypothesize that, QST may provide us detailed information about corneal nerve function alterations and may correlate with morphological nerve changes detected by IVCM. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05758753
Study type	Interventional
Source	Tufts Medical Center
Contact
Status	Enrolling by invitation
Phase	N/A
Start date	May 16, 2023
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03216096` - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease	Phase 1
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT04656197` - The Ocular Microbiome in Patients With Dry Eye Disease
Completed	`NCT05031806` - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease	Phase 1
Completed	`NCT03688802` - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation	Phase 2
Completed	`NCT05213156` - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease	Phase 4
Completed	`NCT04548427` - Study to Evaluate the Efficacy and Safety of CKD-352	Phase 3
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Completed	`NCT02254265` - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca	Phase 2/Phase 3
Completed	`NCT00395759` - The Visual Effect of an Investigational Artificial Tear in the Tear Layer.	N/A
Completed	`NCT00680108` - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution	Phase 2
Recruiting	`NCT06064071` - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD	N/A
Completed	`NCT04139122` - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease	Phase 1/Phase 2
Not yet recruiting	`NCT06375343` - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®	Phase 1
Completed	`NCT01468168` - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients	Phase 2
Completed	`NCT01014078` - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease	Phase 4
Completed	`NCT00799682` - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®	Phase 4
Completed	`NCT05082974` - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)	Phase 3
Recruiting	`NCT06146881` - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia	Phase 2
Completed	`NCT03292809` - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)	Phase 2/Phase 3